PapiVax Biotech, Inc. is a leading biotechnology company dedicated to developing state-of-the-art immunotherapy treatments for HPV infections and related cancers. With a focus on chronic viral infections, especially HPV, our Phase II assets target HPV infections and HPV-related cancers through innovative technology and research.

Our primary technology involves self-adjuvanting DNA vaccines, coupled with a heterologous booster immunization, to deliver a safe and effective immunotherapeutic response. HPV, the most common sexually transmitted infection, is responsible for almost all cervical cancer cases in women and a significant percentage of worldwide cancers.

At PapiVax, we are committed to eradicating HPV-related cancers and improving patient outcomes. Through engagement with stakeholders, including investors and the media, we strive to advance our mission and bring hope to those affected by these challenging diseases. Join us in our journey towards a healthier future.